(18)F-nanobody for PET imaging of HER2 overexpressing tumors.

INTRODUCTION Radiolabeled nanobodies are exciting new probes for molecular imaging due to high affinity, high specificity and fast washout from the blood. Here we present the labeling of an anti-HER2 nanobody with (18)F and its validation for in vivo assessment of HER2 overexpression. METHODS The GMP grade anti-HER2 nanobody was labeled with the prosthetic group, N-succinimidyl-4-[(18)F]fluorobenzoate ([(18)F]-SFB), and its biodistribution, tumor targeting and specificity were evaluated in mouse and rat tumor models. RESULTS [(18)F]FB-anti-HER2 nanobody was prepared with a 5-15% global yield (decay corrected) and a specific activity of 24.7 ± 8.2 MBq/nmol. In vivo studies demonstrated a high specific uptake for HER2 positive xenografts (5.94 ± 1.17 and 3.74 ± 0.52%IA/g, 1 and 3h p.i.) with high tumor-to-blood and tumor-to-muscle ratios generating high contrast PET imaging. The probe presented fast clearance through the kidneys (4%IA/g at 3h p.i.). [(18)F]FB-anti-HER2 nanobody is able to image HER2 expressing tumors when co-administered with the anti-HER2 therapeutic antibody trastuzumab (Herceptin), indicating the possibility of using the tracer in patients undergoing Herceptin therapy. CONCLUSIONS The GMP grade anti-HER2 nanobody was labeled with (18)F. This new PET probe for imaging HER2 overexpression in tumors has ample potential for clinical translation.

[1]  Guy Bormans,et al.  PET Imaging of Macrophage Mannose Receptor–Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments , 2015, The Journal of Nuclear Medicine.

[2]  K. Wester,et al.  HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review , 2004, British Journal of Cancer.

[3]  S. Gambhir,et al.  Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules , 2008, Journal of Nuclear Medicine.

[4]  G. Bormans,et al.  single-domain antibody fragments. , 2015 .

[5]  Alberto Signore,et al.  N-(4-18F-Fluorobenzoyl)Interleukin-2 for PET of Human-Activated T Lymphocytes , 2012, The Journal of Nuclear Medicine.

[6]  J. Steinbach,et al.  Site-selective radiolabeling of peptides by 18F-fluorobenzoylation with [18F]SFB in solution and on solid phase: a comparative study , 2012, Amino Acids.

[7]  T. Randolph.  The two faces of His‐tag: Immune response versus ease of protein purification , 2012, Biotechnology journal.

[8]  S. Gambhir,et al.  A Radiofluorinated Divalent Cystine Knot Peptide for Tumor PET Imaging , 2014, Molecular pharmaceutics.

[9]  S. Muyldermans,et al.  In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT , 2010, Journal of Nuclear Medicine.

[10]  S. Muyldermans,et al.  Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer , 2014, Expert opinion on drug delivery.

[11]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[12]  Marleen Keyaerts,et al.  Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer , 2013, The Journal of Nuclear Medicine.

[13]  Christian Vanhove,et al.  Comparison of the Biodistribution and Tumor Targeting of Two 99mTc-Labeled Anti-EGFR Nanobodies in Mice, Using Pinhole SPECT/Micro-CT , 2008, Journal of Nuclear Medicine.

[14]  A. Sapino,et al.  Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues , 2013, Front. Oncol..

[15]  M. Mottolese,et al.  HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care , 2011, Clinical Cancer Research.

[16]  Wenbin Zeng,et al.  Facile synthesis of N‐succinimidyl 4‐[18F]fluorobenzoate ([18F]SFB) for protein labeling , 2008 .

[17]  S. Muyldermans,et al.  Specific Targeting of Atherosclerotic Plaques in ApoE−/− Mice Using a New Camelid sdAb Binding the Vulnerable Plaque Marker LOX-1 , 2014, Molecular Imaging and Biology.

[18]  Gilles Barone-Rochette,et al.  99mTc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice , 2014, The Journal of Nuclear Medicine.

[19]  G. Antoni,et al.  Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde. , 2014, Bioconjugate chemistry.

[20]  P. De Baetselier,et al.  Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. , 2012, Cancer research.

[21]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[22]  K. Hamacher,et al.  A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation. , 1996, Nuclear medicine and biology.

[23]  H. Lyerly,et al.  Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling , 2014, The Journal of Nuclear Medicine.

[24]  V. Tolmachev.  Choice of Radionuclides and Radiolabelling Techniques , 2008 .

[25]  C. Vanhove,et al.  Correlation Between Epidermal Growth Factor Receptor-Specific Nanobody Uptake and Tumor Burden: A Tool for Noninvasive Monitoring of Tumor Response to Therapy , 2011, Molecular Imaging and Biology.

[26]  M. Piccart.  Closing remarks and treatment guidelines. , 2001, European journal of cancer.

[27]  C. Vanhove,et al.  Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. , 2011, Contrast media & molecular imaging.

[28]  Nick Devoogdt,et al.  Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  Eduard Schreibmann,et al.  18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  N. Devoogdt,et al.  Immuno-imaging using nanobodies. , 2011, Current opinion in biotechnology.

[31]  G. Tomasi,et al.  Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies , 2014, Clinical Cancer Research.

[32]  S. Muyldermans,et al.  Molecular Imaging with Macrophage CRIg-Targeting Nanobodies for Early and Preclinical Diagnosis in a Mouse Model of Rheumatoid Arthritis , 2014, The Journal of Nuclear Medicine.

[33]  S. Muyldermans,et al.  Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody , 2014, Theranostics.

[34]  S. Muyldermans,et al.  Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target , 2013, Expert opinion on biological therapy.

[35]  F. Montemurro,et al.  Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Wanyi Tai,et al.  The role of HER2 in cancer therapy and targeted drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[37]  A. Wu.  Engineered antibodies for molecular imaging of cancer. , 2014, Methods.

[38]  M. Glaser,et al.  Three Methods for 18F Labeling of the HER2-Binding Affibody Molecule ZHER2:2891 Including Preclinical Assessment , 2013, The Journal of Nuclear Medicine.

[39]  Jakub Toczek,et al.  Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions , 2012, Circulation research.

[40]  Zhen Cheng,et al.  Comparison of Two Site-Specifically 18F-Labeled Affibodies for PET Imaging of EGFR Positive Tumors , 2014, Molecular pharmaceutics.

[41]  S. Muyldermans,et al.  Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer. , 2014, Contrast media & molecular imaging.

[42]  A. Wu,et al.  ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging , 2012, Tumor Biology.

[43]  I. Pastan,et al.  Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  G. Griffiths,et al.  The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  H. VanBrocklin,et al.  Assessment of an 18F-Labeled Phosphoramidate Peptidomimetic as a New Prostate-Specific Membrane Antigen–Targeted Imaging Agent for Prostate Cancer , 2009, Journal of Nuclear Medicine.

[46]  A. Santinelli,et al.  HER‐2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy , 2007, International journal of cancer.

[47]  S. Muyldermans,et al.  Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. , 2012, Contrast media & molecular imaging.

[48]  S. Gambhir,et al.  PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  P. De Baetselier,et al.  SPECT Imaging of Joint Inflammation with Nanobodies Targeting the Macrophage Mannose Receptor in a Mouse Model for Rheumatoid Arthritis , 2013, The Journal of Nuclear Medicine.

[50]  G. Adams,et al.  Targeted Radionuclide Tumor Therapy , 2008 .

[51]  C. Vanhove,et al.  SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression , 2008, Molecular Imaging and Biology.

[52]  S. Muyldermans,et al.  Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types , 2010, Journal of Nuclear Medicine.

[53]  S. Muyldermans,et al.  Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging. , 2014, Bioconjugate chemistry.

[54]  G. Hortobagyi,et al.  Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  B. Gulyás,et al.  Fluorine-18 labeling of three novel D-peptides by conjugation with N-succinimidyl-4-[18F]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography. , 2012, Nuclear medicine and biology.

[56]  Funda Meric-Bernstam,et al.  Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy , 2006, Clinical Cancer Research.

[57]  R. Bergmann,et al.  Radiolabelling of isopeptide Nε-(γ-glutamyl)-l-lysine by conjugation with N-succinimidyl-4-[18F]fluorobenzoate , 2003 .

[58]  J. Pickard,et al.  Automated synthesis of the generic peptide labelling agent N-succinimidyl 4-[(18)F]fluorobenzoate and application to (18)F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography. , 2008, Nuclear medicine and biology.

[59]  S. Muyldermans,et al.  Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies , 2014, Leukemia.